Hospital Virgen de la Arrixaca -ko ikertzaileekin lankidetzan egindako argitalpenak (4)

2021

  1. Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- And high-risk myeloma

    Blood, Vol. 137, Núm. 1, pp. 49-60

2020

  1. Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 38, Núm. 8, pp. 784-792

2019

  1. Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis

    Leukemia, Vol. 33, Núm. 5, pp. 1256-1267

2012

  1. Prognostic significance of FLT3 mutational status and expression levels in MLL-AF4 and MLL-germline acute lymphoblastic leukemia

    Leukemia, Vol. 26, Núm. 11, pp. 2360-2366